Regulatory press release

Xintela AB Interim Report January - June 2022

Summary of the interim report
The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480.

Second quarter 2022 for the group
» Income amounted to TSEK 0 (0).
» Loss before tax totalled TSEK 18,942 (loss: 15,020).
» Loss per share was SEK 0.21 (loss: 0.17).

First half year 2022 for the group
» Income amounted to TSEK 0 (0).
» Loss before tax totalled TSEK 35,326 (loss: 26,699).
» Loss per share was SEK 0.40 (loss: 0.30).

Second quarter 2022 for the parent company
» Income amounted to TSEK 0 (0).
» Loss before tax totalled TSEK 11,547 (loss: 11,797).
» Loss per share was SEK 0.13 (loss: 0.13).

First half year 2022 for the parent company
» Income amounted to TSEK 0 (0).
» Loss before tax totalled TSEK 22,589 (loss: 20,842).
» Loss per share was SEK 0.26 (loss: 0.24).
» At June 30, 2022, the equity/assets ratio was -99 % (76).

Significant events in the second quarter of 2022
» Xintela starts clinical study of XSTEM® in knee osteoarthritis. (April 4, 2022)
» Targinta selects ADC-antibody TARG9 as drug candidate. (April 5, 2022)
» Targinta presents new preclinical data on TARG10 at the AACR Annual Meeting. (April 8, 2022)
» Xintela proposes Hans-Joachim Simons as new Board member. (May 3, 2022)
» Xintela publishes results showing that XSTEM repairs damaged joint cartilage in preclinical model. (May 9, 2022)
» Xintela is raising a capital raising that includes a fully guaranteed rights issue of SEK 44.6 million and an over-allotment
option of approximately SEK 10 million. (May 20, 2022)
» Targinta engages Abzena for the production of TARG9 and TARG10. (June 2, 2022)
» Targinta obtains patent grant in Japan. (June 8, 2022)
» Xintela announces timeline for capital raising. (June 15, 2022)
» Xintela publishes a prospectus due to the upcoming rights issue. (June 22, 2022)

Significant events after the end of the period
» Xintela receives approval for clinical study with XSTEM® on difficult-to-heal venous leg ulcers. (July 5, 2022)
» Xintela publishes the outcome of the rights issue and decides on a directed new issue of SEK 10 million. (June, 18 2022)
» Notice of Extraordinary General Meeting in Xintela AB (publ). (July, 18 2022)
» Per Norlén to step down as Targinta CEO. (August 2, 2022)
» Bulletin from the Extraordinary General Meeting in Xintela AB (publ). (August 3, 2022)

The complete interim report is available for download below and on the company’s website www.xintela.se/en/investors#reports

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.